423 related articles for article (PubMed ID: 31980975)
1. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
[TBL] [Abstract][Full Text] [Related]
2. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
[TBL] [Abstract][Full Text] [Related]
3. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
4. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
[TBL] [Abstract][Full Text] [Related]
6. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Heynckes S; Daka K; Franco P; Gaebelein A; Frenking JH; Doria-Medina R; Mader I; Delev D; Schnell O; Heiland DH
BMC Cancer; 2019 Feb; 19(1):117. PubMed ID: 30709339
[TBL] [Abstract][Full Text] [Related]
7. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
8. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines.
Schatz J; Ladinig A; Fietkau R; Putz F; Gaipl US; Frey B; Derer A
Strahlenther Onkol; 2023 Dec; 199(12):1140-1151. PubMed ID: 36480032
[TBL] [Abstract][Full Text] [Related]
9. Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells.
Hasan MN; Luo L; Ding D; Song S; Bhuiyan MIH; Liu R; Foley LM; Guan X; Kohanbash G; Hitchens TK; Castro MG; Zhang Z; Sun D
Theranostics; 2021; 11(3):1295-1309. PubMed ID: 33391535
[No Abstract] [Full Text] [Related]
10. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Dai B; Qi N; Li J; Zhang G
Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Antonios JP; Soto H; Everson RG; Moughon D; Orpilla JR; Shin NP; Sedighim S; Treger J; Odesa S; Tucker A; Yong WH; Li G; Cloughesy TF; Liau LM; Prins RM
Neuro Oncol; 2017 Jun; 19(6):796-807. PubMed ID: 28115578
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.
Zeng J; See AP; Phallen J; Jackson CM; Belcaid Z; Ruzevick J; Durham N; Meyer C; Harris TJ; Albesiano E; Pradilla G; Ford E; Wong J; Hammers HJ; Mathios D; Tyler B; Brem H; Tran PT; Pardoll D; Drake CG; Lim M
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):343-9. PubMed ID: 23462419
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
Hartley GP; Chow L; Ammons DT; Wheat WH; Dow SW
Cancer Immunol Res; 2018 Oct; 6(10):1260-1273. PubMed ID: 30012633
[TBL] [Abstract][Full Text] [Related]
15. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice.
Zhao K; Calero-Pérez P; Bopp MHA; Möschl V; Pagenstecher A; Mulero-Acevedo M; Vázquez M; Barcia C; Arús C; Nimsky C; Rusch T; Bartsch JW; Candiota AP
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139457
[TBL] [Abstract][Full Text] [Related]
16. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
17. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
Puigdelloses M; Garcia-Moure M; Labiano S; Laspidea V; Gonzalez-Huarriz M; Zalacain M; Marrodan L; Martinez-Velez N; De la Nava D; Ausejo I; Hervás-Stubbs S; Herrador G; Chen Z; Hambardzumyan D; Patino Garcia A; Jiang H; Gomez-Manzano C; Fueyo J; Gállego Pérez-Larraya J; Alonso M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34281988
[TBL] [Abstract][Full Text] [Related]
18. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
19. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
[TBL] [Abstract][Full Text] [Related]
20. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
